Benzinga | Apr 1, 2021 12:34PM EDT

Truist Securities Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $127

Truist Securities analyst Robyn Karnauskas maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $150 to $127.